Cargando…
Self-Emulsifying Formulations to Increase the Oral Bioavailability of 4,6,4′-Trimethylangelicin as a Possible Treatment for Cystic Fibrosis
4,6,4′-trimethylangelicin (TMA) is a promising pharmacological option for the treatment of cystic fibrosis (CF) due to its triple-acting behavior toward the function of the CF transmembrane conductance regulator. It is a poorly water-soluble drug, and thus it is a candidate for developing a self-emu...
Autores principales: | Franceschinis, Erica, Roverso, Marco, Gabbia, Daniela, De Martin, Sara, Brusegan, Matteo, Vaccarin, Christian, Bogialli, Sara, Chilin, Adriana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9506254/ https://www.ncbi.nlm.nih.gov/pubmed/36145554 http://dx.doi.org/10.3390/pharmaceutics14091806 |
Ejemplares similares
-
Improved Trimethylangelicin Analogs for Cystic Fibrosis: Design, Synthesis and Preliminary Screening
por: Vaccarin, Christian, et al.
Publicado: (2022) -
Molecular Mechanism of Action of Trimethylangelicin Derivatives as CFTR Modulators
por: Laselva, Onofrio, et al.
Publicado: (2018) -
New TMA (4,6,4′-Trimethyl angelicin) Analogues as Anti-Inflammatory Agents in the Treatment of Cystic Fibrosis Lung Disease
por: Tupini, Chiara, et al.
Publicado: (2022) -
4,6,4′-Trimethylangelicin Photoactivated by Blue Light Might Represent an Interesting Option for Photochemotherapy of Non-Invasive Bladder Carcinoma: An In Vitro Study on T24 Cells
por: Sturaro, Giulio, et al.
Publicado: (2021) -
Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice
por: Oostendorp, Roos L., et al.
Publicado: (2010)